Key Drivers of Coagulation Factor Use in Von Willebrand Disease During Hospitalization: An Overview of the French BERHLINGO Cohort
Authors:
- Valérie HorvaisVHValérie Horvais
- Philippe BeurrierPBPhilippe Beurrier
- Vincent CussacVCVincent Cussac
- Brigitte Pan-PeteschBPBrigitte Pan-Petesch
- Solène Schirr-BonnansSSSolène Schirr-Bonnans
- Johann RoseJRJohann Rose
- Sophie BayartSBSophie Bayart
- Catherine TernisienCTCatherine Ternisien
- Marc FouassierMFMarc Fouassier
- Marianne SigaudMSMarianne Sigaud
- Antoine BabutyABAntoine Babuty
- Nicolas DrillaudNDNicolas Drillaud
- 30 November 2023
- journal article
- research article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 44 (1) , 35-49
Abstract
Background Von Willebrand disease (VWD) is the most common inherited bleeding disorder. However, studies of hospitalisation patterns with replacement treatment are scarce. Objectives The aim of this study was to investigate the current therapeutic management of VWD and determine the key drivers of coagulation factor uses in patients during hospitalisation. Methods Hopscotch-WILL was a multi-centric retrospective study conducted over a 48-month period in any patients with VWD. The data were collected from the BERHLINGO Research Database and the French Hospital database. Results A total of 988 patients were included; 153 patients (15%) were hospitalised during 293 stays requiring treatment with von Willebrand factor (VWF) concentrates—pure or in association with Factor VIII (FVIII). Their median basal concentrations of VWF and FVIII were significantly lower than in untreated patients: VWF antigen < 30 IU/dL, VWF activity < 20 IU/dL and FVIII:C < 40 IU/dL. The median (interquartile range) concentrate consumption was similar between highly purified VWF or VWF combined with FVIII (72 [110] vs 57 [89] IU/kg/stay, p = 0.154). The use of VWF was highly heterogeneous by VWD type; type 3 had a particularly high impact on VWF consumption in non-surgical situations. The main admissions were for ear/nose/throat, hepato-gastroenterology, and trauma/orthopaedic conditions, besides gynaecological-obstetric causes in women. Conclusions The use of VWF concentrates is mostly influenced by low basal levels of VWF and FVIII, but also by VWD type or the cause for hospitalisation. These results could inform future studies of newly released recombinant VWF.Keywords
Funding Information
- Baxalta GmbH, a wholly subsidiary of Takeda Pharmaceutical Company Limited (IIR-FXX-002472)
This publication has 34 references indexed in Scilit:
- Cost–consequence analysis of long-term prophylaxis in the treatment of von Willebrand disease in the Italian contextClinicoEconomics and Outcomes Research, 2014
- Cost-Consequences Analysis of the Long-Term Prophylaxis In A Type 1 Von Willebrand Disease Patient With Recurrent Bleedings In ItalyValue in Health, 2014
- Enhancing haemophilia care through registriesHaemophilia, 2014
- Management of Inheritedvon Willebrand Disease in Italy: Results from the Retrospective Study on 1234 PatientsSeminars in Thrombosis and Hemostasis, 2011
- von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand diseaseHaemophilia, 2011
- Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgeryThrombosis and Haemostasis, 2011
- Efficacy and safety of highly purified, doubly virus‐inactivated VWF/FVIII concentrates in inherited von Willebrand’s disease: results of an Italian cohort study on 120 patients characterized by bleeding severity scoreHaemophilia, 2009
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007
- von Willebrand factor/factor VIII concentrate (Haemate® P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgeryJournal of Thrombosis and Haemostasis, 2007
- Treatment of severe von Willebrand disease with a high‐purity von Willebrand factor concentrate (Wilfactin®): a prospective study of 50 patientsJournal of Thrombosis and Haemostasis, 2007